WHG
CPRX

Westwood Holdings Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Westwood Holdings Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,204
Closed -$234K – 569
2022
Q3 		$234K Buy
+18,204
New +$216K ﹤0.01% 431

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Westwood Holdings Group's CPRX Position: Q4 2022 in Review

Westwood Holdings Group sold out of Catalyst Pharmaceutical (CPRX) in Q4 2022, closing a stake of 18,204 shares — an estimated $234K sold.

Westwood Holdings Group first reported a position in CPRX in Q3 2022 and held it in 1 quarter. The position peaked at $234K in Q3 2022. 257 funds tracked by Wall St. Rank hold CPRX as of Q4 2022.

  • Westwood Holdings Group reported no remaining Catalyst Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Westwood Holdings Group sold 18,204 Catalyst Pharmaceutical shares in Q4 2022, an estimated $234K.
  • Westwood Holdings Group first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 1 quarter.
  • Westwood Holdings Group's Catalyst Pharmaceutical position peaked at $234K in Q3 2022.
  • 257 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2022.

Based on Westwood Holdings Group's 13F filing for Q4 2022, filed 14 Feb 2023.